Patients currently enrolled in other clinical trials testing a therapeutic intervention Patients must not plan to participate in any other clinical trials while receiving treatment on this study or being followed post-protocol therapy Has participated in Merck MK- (pembrolizumab) clinical trials Participation in other clinical trials within at least weeks of the first ORH- dose; Patients being treated with any other experimental agents/clinical trials are not eligible for participation; if the patient is on any investigational agent, a wash-out period of minimum weeks prior to registration is mandatory for the patient to be eligible for the study No concurrent treatment on another clinical trial; supportive care trials or nontreatment trials, e.g. quality of life, are allowed Clinical trials prior to enrollment are allowed, as long as no brain directed therapy was included (current treatment trials are exclusionary) Participant in other clinical trials Concurrent participation in other investigational drug trials. Participation in other clinical trials with the same primary endpoint Subject is participating in any other therapeutic clinical study (observational or registry trials are allowed) Patients are eligible if they undergo a targeted treatment recommended by the Molecular Tumor Board, excluding clinical trials Participating in any other clinical trials using an investigational product. Simultaneous participation in other therapeutic clinical trials will not be allowed In accordance with National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) policy, protocol treatment is to begin within working days of patient registration Measurable disease by the criteria proposed by the acquired immunodeficiency syndrome (AIDS) Clinical Trials Group Oncology Committee (for KS) Simultaneous participation in other therapeutic clinical trials will be allowed Participation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases. EXCLUSION CRITERIA FOR REGISTRATION: subjects should not be participating in other clinical trials of interventions designed to reduce risk of ovarian cancer recurrence or plan to receive off protocol maintenance therapy (e.g. paclitaxel or bevacizumab) Any other investigational treatments within weeks prior to and during study; includes participation in any medical device or other therapeutic intervention clinical trials Enrolled in another clinical trial with a targeted endpoint of treating the patients cancer (observational trials are acceptable) Subjects who have recently been enrolled in other experimental clinical trials of\n investigational agents Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowed Patients who currently are participating in other phase III therapeutic clinical trials and/or who have participated in other phase III therapeutic clinical trials in the previous days Participation in concurrent clinical trials evaluating treatment intervention(s) Not be receiving neoadjuvant hormonal or chemotherapy (other clinical trials) Participation in the active phase of other clinical trials of investigational agents in which last study treatment was administered within weeks prior to randomization Participant has participated in clinical trials of experimental agents within weeks prior to randomization Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowed Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), and imaging trials, are allowed Participation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases. Patients enrolled in other clinical trials must have received their last treatment at least weeks prior to enrollment Simultaneous participation in other therapeutic clinical trials will not be allowed Patients receiving or participating on any other experimental agents/clinical trials are not eligible for participation Concurrent treatment on another clinical trial; supportive care trials or non-treatment (i.e. quality of life) are allowed Patients who have participated in other interventional (treatment-related) clinical trials within days of enrollment are excluded Patients who are enrolled in other symptom management or symptom clinical trials Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowed Patients who are enrolled in a national/international cooperative group trials Treatment with any known non-marketed drug substance or experimental therapy within weeks prior to enrollment, or currently participating in any other interventional clinical study for NHL or any other illness (except observational and registry trials) Participation in clinical drug trials within weeks Registered with Clinical Trials Office at Karmanos Cancer Institute/Wayne State University Concurrent treatment on another clinical trial; supportive care trials, surgical clinical trials, or non-treatment trials, e.g. quality of life (QOL), are allowed Simultaneous participation in other therapeutic clinical trials will not be allowed Treatment with any known non-marketed drug substance or experimental therapy within weeks prior to enrollment, or currently participating in any other interventional clinical study for NHL or any other illness (except observational, prevention, and/or registry trials) Patients must not co-enroll on other treatment trials Concurrent treatment on another clinical trial; supportive care trials or non-therapeutic trials (i.e. quality of life) are allowed Participants may be enrolled on other treatment-based clinical trials but may not be enrolled on any other weight loss trials Patients enrolled on other supportive care intervention trials Individuals who are enrolled on oral chemotherapy clinical trials will also be excluded Patients who are enrolled in other clinical trials that have symptom management as primary outcome Patients who are enrolled in other symptom management clinical trials Patients may concurrently participate in other therapeutic clinical trials Patients are permitted to participate in other clinical trials while participating in this trial Participants in other ongoing clinical trials are eligible for this study No concurrent or planned participation in randomized trials of weight loss or exercise interventions or trials targeting insulin, insulin-like growth factor (IGF-) or their receptors Registered with the clinical trials office of the Karmanos Cancer Center/Wayne State University Enrollment into this study may occur in tandem with other clinical therapeutics trials occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does not violate protocol or inclusion criteria of that study Patients preparing to receive therapy for pancreas cancer, including patients enrolled in HRPO# or other clinical trials, are eligible Patients must not be participating or plan to participate in other clinical trials that involve investigational systemic cancer treatments or investigational uses of CSF during their first months after registration Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed; patients may be enrolled to other clinical trials after completing all of the baseline interventions and measures Be interventional trials